News

The true disruptor is Tirzepatide, the world's first GIP/GLP-1 dual receptor agonist. In the SURPASS series of trials, it reduced glycated hemo...

GLP-1 is encoded by the glucagon gene (GCG) and is cleaved by protease PC1/3 to produce two active forms: GLP-1 (7-36) amide (80%) and GLP-1 (7-37)...

Glucagon like peptide-1 ( GLP-1 ), also known as Glucagon Like Peptide-1, is a 30 amino acid peptide hormone secreted by intestinal L cells and is ...

On May 11, 2026, Fractyl Health announced that it has obtained approval for a clinical trial application in the Netherlands and will initiate the f...

On May 8, 2026, Anjin registered the GIPR antibody coupled GLP-1 new drug AMG 133 (Maridebart Caffraglutide) on the Clinicaltrials.gov website for ...

On January 28, 2026, Shandong Shengdi Pharmaceutical Co., Ltd., a subsidiary of Hengrui Pharmaceutical, received the "Drug Clinical Trial Appr...

On January 26, 2026, Geli Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange Code: 1672, referred to as "Geli") announced today that its ...

Recently, Anlong Biotechnology and Sunshine Novo jointly announced that the clinical trial application for the innovative hypertension drug ABA001,...

On October 13, 2025, Shiyao Group (1093. HK) announced that its subsidiary, Shiyao Group Baike (Shandong) Biopharmaceutical Co., Ltd., has received...

Recently, Rein Therapeutics (referred to as "Rein", NASDAQ stock code: RNTX), a biopharmaceutical company, announced that it has been aut...

On October 9, 2025, Chengdu Newruit Medical Technology Co., Ltd. (hereinafter referred to as Newruit Medical) recently completed a Series D financi...

On September 29, 2025, Metsera (acquired by Pfizer) announced positive results from two weight loss phase 1b studies (VESPER-1 and VESPER-13) of ME...